Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients

Hyun S. Kim, Stephen R. Preece, James Hamilton Black, Luu D. Pham, Michael B Streiff

Research output: Contribution to journalArticle

Abstract

Background: The current study was conducted to demonstrate that catheter-directed thrombolysis for upper and lower extremity deep vein thrombosis is equally safe in patients with and without cancer. Methods: A retrospective cohort of consecutive patients with acute iliofemoral or brachiosubclavian deep vein thrombosis treated with catheter-directed thrombolysis was identified. Demographic characteristics and clinical outcomes were compared between patients with cancer and without cancer. Results: Catheter-directed thrombolysis was used to treat 202 limbs in 178 patients (75 limbs in 61 cancer patients and 127 limbs in 117 patients without cancer). The mean treatment duration for patients with cancer (29.7 ± 21.2 hours) and without cancer (28.8 ± 22.2 hours) was similar (P = .7774). Catheter-directed thrombolysis achieved grade III clot lysis in a similar proportion of cancer patients (50 of 75 limbs, 66.7%) and patients without cancer (82 of 127 limbs, 64.6%; P = .7619). Grade II clot lysis also was achieved in equal numbers of patients with (20 of 75 limbs, 26.7%) and without cancer (34 of 127 limbs, 26.8%; P = .9872). Three cancer patients (4.9%) and four noncancer patients (3.4%) experienced major bleeding during catheter-directed thrombolysis (P = .6924). Pulmonary embolism occurred in 1.6% (1 of 61) of cancer patients and in 1.7% (2 of 117) of patients without cancer (P = .9999) during catheter-directed thrombolysis. Patients aged ≥70 years had an increased risk of major bleeding. Conclusion: Percutaneous catheter-directed thrombolysis is equally safe for patients with and without cancer who have acute symptomatic deep vein thrombosis.

Original languageEnglish (US)
Pages (from-to)388-394
Number of pages7
JournalJournal of Vascular Surgery
Volume47
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Venous Thrombosis
Catheters
Safety
Neoplasms
Extremities
Upper Extremity Deep Vein Thrombosis
Hemorrhage
Pulmonary Embolism
Lower Extremity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. / Kim, Hyun S.; Preece, Stephen R.; Black, James Hamilton; Pham, Luu D.; Streiff, Michael B.

In: Journal of Vascular Surgery, Vol. 47, No. 2, 02.2008, p. 388-394.

Research output: Contribution to journalArticle

@article{7e1650ee808c4adab8ac6403180cade0,
title = "Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients",
abstract = "Background: The current study was conducted to demonstrate that catheter-directed thrombolysis for upper and lower extremity deep vein thrombosis is equally safe in patients with and without cancer. Methods: A retrospective cohort of consecutive patients with acute iliofemoral or brachiosubclavian deep vein thrombosis treated with catheter-directed thrombolysis was identified. Demographic characteristics and clinical outcomes were compared between patients with cancer and without cancer. Results: Catheter-directed thrombolysis was used to treat 202 limbs in 178 patients (75 limbs in 61 cancer patients and 127 limbs in 117 patients without cancer). The mean treatment duration for patients with cancer (29.7 ± 21.2 hours) and without cancer (28.8 ± 22.2 hours) was similar (P = .7774). Catheter-directed thrombolysis achieved grade III clot lysis in a similar proportion of cancer patients (50 of 75 limbs, 66.7{\%}) and patients without cancer (82 of 127 limbs, 64.6{\%}; P = .7619). Grade II clot lysis also was achieved in equal numbers of patients with (20 of 75 limbs, 26.7{\%}) and without cancer (34 of 127 limbs, 26.8{\%}; P = .9872). Three cancer patients (4.9{\%}) and four noncancer patients (3.4{\%}) experienced major bleeding during catheter-directed thrombolysis (P = .6924). Pulmonary embolism occurred in 1.6{\%} (1 of 61) of cancer patients and in 1.7{\%} (2 of 117) of patients without cancer (P = .9999) during catheter-directed thrombolysis. Patients aged ≥70 years had an increased risk of major bleeding. Conclusion: Percutaneous catheter-directed thrombolysis is equally safe for patients with and without cancer who have acute symptomatic deep vein thrombosis.",
author = "Kim, {Hyun S.} and Preece, {Stephen R.} and Black, {James Hamilton} and Pham, {Luu D.} and Streiff, {Michael B}",
year = "2008",
month = "2",
doi = "10.1016/j.jvs.2007.10.033",
language = "English (US)",
volume = "47",
pages = "388--394",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients

AU - Kim, Hyun S.

AU - Preece, Stephen R.

AU - Black, James Hamilton

AU - Pham, Luu D.

AU - Streiff, Michael B

PY - 2008/2

Y1 - 2008/2

N2 - Background: The current study was conducted to demonstrate that catheter-directed thrombolysis for upper and lower extremity deep vein thrombosis is equally safe in patients with and without cancer. Methods: A retrospective cohort of consecutive patients with acute iliofemoral or brachiosubclavian deep vein thrombosis treated with catheter-directed thrombolysis was identified. Demographic characteristics and clinical outcomes were compared between patients with cancer and without cancer. Results: Catheter-directed thrombolysis was used to treat 202 limbs in 178 patients (75 limbs in 61 cancer patients and 127 limbs in 117 patients without cancer). The mean treatment duration for patients with cancer (29.7 ± 21.2 hours) and without cancer (28.8 ± 22.2 hours) was similar (P = .7774). Catheter-directed thrombolysis achieved grade III clot lysis in a similar proportion of cancer patients (50 of 75 limbs, 66.7%) and patients without cancer (82 of 127 limbs, 64.6%; P = .7619). Grade II clot lysis also was achieved in equal numbers of patients with (20 of 75 limbs, 26.7%) and without cancer (34 of 127 limbs, 26.8%; P = .9872). Three cancer patients (4.9%) and four noncancer patients (3.4%) experienced major bleeding during catheter-directed thrombolysis (P = .6924). Pulmonary embolism occurred in 1.6% (1 of 61) of cancer patients and in 1.7% (2 of 117) of patients without cancer (P = .9999) during catheter-directed thrombolysis. Patients aged ≥70 years had an increased risk of major bleeding. Conclusion: Percutaneous catheter-directed thrombolysis is equally safe for patients with and without cancer who have acute symptomatic deep vein thrombosis.

AB - Background: The current study was conducted to demonstrate that catheter-directed thrombolysis for upper and lower extremity deep vein thrombosis is equally safe in patients with and without cancer. Methods: A retrospective cohort of consecutive patients with acute iliofemoral or brachiosubclavian deep vein thrombosis treated with catheter-directed thrombolysis was identified. Demographic characteristics and clinical outcomes were compared between patients with cancer and without cancer. Results: Catheter-directed thrombolysis was used to treat 202 limbs in 178 patients (75 limbs in 61 cancer patients and 127 limbs in 117 patients without cancer). The mean treatment duration for patients with cancer (29.7 ± 21.2 hours) and without cancer (28.8 ± 22.2 hours) was similar (P = .7774). Catheter-directed thrombolysis achieved grade III clot lysis in a similar proportion of cancer patients (50 of 75 limbs, 66.7%) and patients without cancer (82 of 127 limbs, 64.6%; P = .7619). Grade II clot lysis also was achieved in equal numbers of patients with (20 of 75 limbs, 26.7%) and without cancer (34 of 127 limbs, 26.8%; P = .9872). Three cancer patients (4.9%) and four noncancer patients (3.4%) experienced major bleeding during catheter-directed thrombolysis (P = .6924). Pulmonary embolism occurred in 1.6% (1 of 61) of cancer patients and in 1.7% (2 of 117) of patients without cancer (P = .9999) during catheter-directed thrombolysis. Patients aged ≥70 years had an increased risk of major bleeding. Conclusion: Percutaneous catheter-directed thrombolysis is equally safe for patients with and without cancer who have acute symptomatic deep vein thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=38649119484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649119484&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2007.10.033

DO - 10.1016/j.jvs.2007.10.033

M3 - Article

C2 - 18241762

AN - SCOPUS:38649119484

VL - 47

SP - 388

EP - 394

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 2

ER -